{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:36:13Z","timestamp":1791200173870,"version":"4.2.0"},"reference-count":67,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T00:00:00Z","timestamp":1275523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openmicrobiologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOMICROJ"],"published-print":{"date-parts":[[2010,6,3]]},"abstract":"<jats:p>Successful treatment of inhalation anthrax, pneumonic plague and tularemia can be achieved with fluoroquinolone antibiotics, such as ciprofloxacin and levofloxacin, and initiation of treatment is most effective when administered as soon as possible following exposure. Bacillus anthracis Ames, Yersinia pestis CO92, and Francisella tularensis SCHU S4 have equivalent susceptibility in vitro to ciprofloxacin and levofloxacin (minimal inhibitory concentration is 0.03 \u03bcg\/ml); however, limited information is available regarding in vivo susceptibility of these infectious agents to the fluoroquinolone antibiotics in small animal models. Mice, guinea pig, and rabbit models have been developed to evaluate the protective efficacy of antibiotic therapy against these life-threatening infections. Our results indicated that doses of ciprofloxacin and levofloxacin required to protect mice against inhalation anthrax were approximately 18-fold higher than the doses of levofloxacin required to protect against pneumonic plague and tularemia. Further, the critical period following aerosol exposure of mice to either B. anthracis spores or Y. pestis was 24 h, while mice challenged with F. tularensis could be effectively protected when treatment was delayed for as long as 72 h postchallenge. In addition, it was apparent that prolonged antibiotic treatment was important in the effective treatment of inhalation anthrax in mice, but short-term treatment of mice with pneumonic plague or tularemia infections were usually successful. These results provide effective antibiotic dosages in mice, guinea pigs, and rabbits and lay the foundation for the development and evaluation of combinational treatment modalities.<\/jats:p>","DOI":"10.2174\/1874285801004010034","type":"journal-article","created":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T00:48:57Z","timestamp":1288918137000},"page":"34-46","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis"],"prefix":"10.2174","volume":"4","author":[{"given":"Johnny W","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T","family":"Moen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Taormina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hardcastle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagram M","family":"Chatuev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T","family":"Gnade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri M","family":"Foltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L","family":"Agar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R","family":"Klimpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L","family":"Kirtley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonyia","family":"Eaves-Pyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-8518-2-5","volume":"2","author":"Sawada-Hirai R","year":"2004","unstructured":"Sawada-Hirai R, Jiang I, Wang F, et al. \n                Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed \n                J Immune Based Ther Vaccines  \n                2004; \n                2\n                : 1-5.","journal-title":"J Immune Based Ther Vaccines"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1086\/427189","volume":"191","author":"Cui X","year":"2005","unstructured":"Cui X, Li Y, Moayeri M, Choi GH, et al. \n                Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis \n                J Infect Dis  \n                2005; \n                191\n                : 422-34.","journal-title":"J Infect Dis"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/HAB-2004-13402","volume":"13","author":"Wang F","year":"2004","unstructured":"Wang F, Ruther P, Jiang I, et al. \n                Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly \n                Hum Antibodies  \n                2004; \n                13\n                : 105-10.","journal-title":"Hum Antibodies"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/IAI.74.2.1016-1024.2006","volume":"74","author":"Peterson JW","year":"2006","unstructured":"Peterson JW, Comer JE, Noffsinger DM, et al. \n                Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax \n                Infect Immun  \n                2006; \n                74\n                : 1016-24.","journal-title":"Infect Immun"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1128\/IAI.00712-06","volume":"74","author":"Vitale L","year":"2006","unstructured":"Vitale L, Blanset D, Lowy I, et al. \n                Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity \n                Infect Immun  \n                2006; \n                74\n                : 5840-7.","journal-title":"Infect Immun"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.01184-06","volume":"51","author":"Sanchez AM","year":"2007","unstructured":"Sanchez AM, Thomas D, Gillespie EJ, et al. \n                Amiodarone and bepridil inhibit anthrax toxin entry into host cells \n                Antimicrob Agents Chemother  \n                2007; \n                51\n                : 2403-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/15287390500360281","volume":"69","author":"Comer JE","year":"2006","unstructured":"Comer JE, Noffsinger DM, McHenry DJ, et al. \n                Evaluation of the protective effects of quinacrine against Bacillus anthracis Ames \n                J Toxicol Environ Health A  \n                2006; \n                69\n                : 1083-95.","journal-title":"J Toxicol Environ Health A"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bioorg.2006.12.005","volume":"35","author":"Johnson SL","year":"2007","unstructured":"Johnson SL, Chen LH, Pellecchia M. \n                A high-throughput screening approach to anthrax lethal factor inhibition \n                Bioorg Chem  \n                2007; \n                35\n                : 306-12.","journal-title":"Bioorg Chem"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.vaccine.2005.10.018","volume":"24","author":"Hepler RW","year":"2006","unstructured":"Hepler RW, Kelly R, McNeely TB, et al. \n                A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection \n                Vaccine  \n                2006; \n                24\n                : 1501-4.","journal-title":"Vaccine"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.1016\/j.vaccine.2007.09.063","volume":"25","author":"Gupta M","year":"2007","unstructured":"Gupta M, Alam S, Bhatnagar R. \n                Catalytically inactive anthrax toxin(s) are potential prophylactic agents \n                Vaccine  \n                2007; \n                25\n                : 8410-9.","journal-title":"Vaccine"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1196\/annals.1348.030","volume":"1082","author":"Klinman DM","year":"2006","unstructured":"Klinman DM, Xie H, Ivins BE. \n                CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine \n                Ann N Y Acad Sci  \n                2006; \n                1082\n                : 137-50.","journal-title":"Ann N Y Acad Sci"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jac\/41.2.301","volume":"41","author":"Russell P","year":"1998","unstructured":"Russell P, Eley SM, Green M, et al. \n                Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection \n                J Antimicrob Chemother  \n                1998; \n                41\n                : 301-5.","journal-title":"J Antimicrob Chemother"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/clinids\/19.1.42","volume":"19","author":"Enderlin G","year":"1994","unstructured":"Enderlin G, Morales L, Jacobs RF, Cross JT. \n                Streptomycin and alternative agents for the treatment of tularemia: review of the literature \n                Clin Infect Dis  \n                1994; \n                19\n                : 42-7.","journal-title":"Clin Infect Dis"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/AAC.42.3.675","volume":"42","author":"Byrne WR","year":"1998","unstructured":"Byrne WR, Welkos SL, Pitt ML, et al. \n                Antibiotic treatment of experimental pneumonic plague in mice \n                Antimicrob Agents Chemother  \n                1998; \n                42\n                : 675-81.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","volume":"283","author":"Inglesby TV","year":"2000","unstructured":"Inglesby TV, Dennis DT, Henderson DA, et al. \n                Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense \n                JAMA  \n                2000; \n                283\n                : 2281-90.","journal-title":"JAMA"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.micpath.2006.09.003","volume":"42","author":"Williamson ED","year":"2007","unstructured":"Williamson ED, Flick-Smith HC, Waters E, et al. \n                Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates \n                Microb Pathog  \n                2007; \n                42\n                : 11-21.","journal-title":"Microb Pathog"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1365-2672.2001.01497.x","volume":"91","author":"Williamson ED","year":"2001","unstructured":"Williamson ED. \n                Plague vaccine research and development \n                J Appl Microbiol  \n                2001; \n                91\n                : 606-8.","journal-title":"J Appl Microbiol"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14760584.3.3.307","volume":"3","author":"Conlan JW","year":"2004","unstructured":"Conlan JW. \n                Vaccines against Francisella tularensis--past, present and future \n                Expert Rev Vaccines  \n                2004; \n                3\n                : 307-14.","journal-title":"Expert Rev Vaccines"},{"key":"refR19","unstructured":"Amsden GW. \n                Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.  6th. \n                Livingstone: Philadelphia: Elsevier Churchill 2005; 1."},{"key":"refR20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(03)00061-8","volume":"17","author":"Ambrose PG","year":"2003","unstructured":"Ambrose PG, Bhavnani SM, Owens RC Jr. \n                Clinical pharmacodynamics of quinolones \n                Infect Dis Clin North Am  \n                2003; \n                17\n                : 529-43.","journal-title":"Infect Dis Clin North Am"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"Craig WA","year":"1998","unstructured":"Craig WA. \n                Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men \n                Clin Infect Dis  \n                1998; \n                26\n                : 1-10.\n                \n                \n             quiz 1-2","journal-title":"Clin Infect Dis"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","volume":"19","author":"Andes D","year":"2002","unstructured":"Andes D, Craig WA. \n                Animal model pharmacokinetics and pharmacodynamics: a critical review \n                Int J Antimicrob Agents  \n                2002; \n                19\n                : 261-8.","journal-title":"Int J Antimicrob Agents"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1128\/AAC.00251-07","volume":"51","author":"Ambrose PG","year":"2007","unstructured":"Ambrose PG, Forrest A, Craig WA, et al. \n                Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model \n                Antimicrob Agents Chemother  \n                2007; \n                51\n                : 4351-5.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1128\/IAI.72.8.4801-4809.2004","volume":"72","author":"Lyons CR","year":"2004","unstructured":"Lyons CR, Lovchik J, Hutt J, et al. \n                Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility \n                Infect Immun  \n                2004; \n                72\n                : 4801-9.","journal-title":"Infect Immun"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jac\/dkh276","volume":"54","author":"Steward J","year":"2004","unstructured":"Steward J, Lever MS, Simpson AJ, Sefton AM, Brooks TJ. \n                Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones \n                J Antimicrob Chemother  \n                2004; \n                54\n                : 95-.","journal-title":"J Antimicrob Chemother"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/37.4.769","volume":"37","author":"Russell P","year":"1996","unstructured":"Russell P, Eley SM, Bell DL, Manchee RJ, Titball RW. \n                Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice \n                J Antimicrob Chemother  \n                1996; \n                37\n                : 769-4.","journal-title":"J Antimicrob Chemother"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1128\/AAC.00073-07","volume":"51","author":"Louie A","year":"2007","unstructured":"Louie A, Deziel MR, Liu W, Drusano GL. \n                Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy \n                Antimicrob Agents Chemother  \n                2007; \n                51\n                : 2661-7.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ijantimicag.2004.06.011","volume":"24","author":"Steward J","year":"2004","unstructured":"Steward J, Lever MS, Russell P, et al. \n                Efficacy of the latest fluoroquinolones against experimental Yersinia pestis \n                Int J Antimicrob Agents  \n                2004; \n                24\n                : 609-12.","journal-title":"Int J Antimicrob Agents"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/jac\/41.4.461","volume":"41","author":"Russell P","year":"1998","unstructured":"Russell P, Eley SM, Fulop MJ, Bell DL, Titball RW. \n                The efficacy of ciprofloxacin and doxycycline against experimental tularaemia \n                J Antimicrob Chemother  \n                1998; \n                41\n                : 461-5.","journal-title":"J Antimicrob Chemother"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jac\/dki359","volume":"56","author":"Piercy T","year":"2005","unstructured":"Piercy T, Steward J, Lever MS, Brooks TJ. \n                In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice \n                J Antimicrob Chemother  \n                2005; \n                56\n                : 1069-73.","journal-title":"J Antimicrob Chemother"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijantimicag.2006.02.006","volume":"27","author":"Steward J","year":"2006","unstructured":"Steward J, Piercy T, Lever MS, Simpson AJ. \n                Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin \n                Int J Antimicrob Agents  \n                2006; \n                27\n                : 439-.","journal-title":"Int J Antimicrob Agents"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1128\/AAC.00453-08","volume":"52","author":"Drusano GL","year":"2008","unstructured":"Drusano GL, Okusanya OO, Okusanya A, et al. \n                Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? \n                Antimicrob Agents Chemother  \n                2008; \n                52\n                : 3973-9.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1128\/AAC.01439-07","volume":"52","author":"Louie A","year":"2008","unstructured":"Louie A, Heine HS, Kim K, et al. \n                Use of an in vitro pharmaco-dynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis \n                Antimicrob Agents Chemother  \n                2008; \n                52\n                : 2486-96.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","volume":"167","author":"Friedlander AM","year":"1993","unstructured":"Friedlander AM, Welkos SL, Pitt ML, et al. \n                Postexposure prophylaxis against experimental inhalation anthrax \n                J Infect Dis  \n                1993; \n                167\n                : 1239-43.","journal-title":"J Infect Dis"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1086\/596063","volume":"199","author":"Vietri NJ","year":"2009","unstructured":"Vietri NJ, Purcell BK, Tobery SA, et al. \n                A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics \n                J Infect Dis  \n                2009; \n                199\n                : 336-41.","journal-title":"J Infect Dis"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1128\/AAC.00090-06","volume":"50","author":"Kao LM","year":"2006","unstructured":"Kao LM, Bush K, Barnewall R, et al. \n                Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model \n                Antimicrob Agents Chemother  \n                2006; \n                50\n                : 3535-42.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1128\/AAC.49.12.5099-5106.2005","volume":"49","author":"Deziel MR","year":"2005","unstructured":"Deziel MR, Heine H, Louie A, et al. \n                Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis \n                Antimicrob Agents Chemother  \n                2005; \n                49\n                : 5099-106.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1128\/IAI.70.11.6231-6241.2002","volume":"70","author":"Altboum Z","year":"2002","unstructured":"Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D. \n                Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs \n                Infect Immun  \n                2002; \n                70\n                : 6231-41.","journal-title":"Infect Immun"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1073\/pnas.0502159102","volume":"102","author":"Shoop WL","year":"2005","unstructured":"Shoop WL, Xiong Y, Wiltsie J, et al. \n                Anthrax lethal factor inhibition \n                Proc Natl Acad Sci USA  \n                2005; \n                102\n                : 7958-63.","journal-title":"Proc Natl Acad Sci USA"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/AAC.01050-06","volume":"51","author":"Heine HS","year":"2007","unstructured":"Heine HS, Bassett J, Miller L, et al. \n                Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model \n                Antimicrob Agents Chemother  \n                2007; \n                51\n                : 1373-9.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10156-004-0303-9","volume":"10","author":"Kihira T","year":"2004","unstructured":"Kihira T, Sato J, Shibata T. \n                Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis \n                J Infect Chemother  \n                2004; \n                10\n                : 97-100.","journal-title":"J Infect Chemother"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1473-3099(03)00658-3","volume":"3","author":"Dalhoff A","year":"2003","unstructured":"Dalhoff A, Shalit I. \n                Immunomodulatory effects of quinolones \n                Lancet Infect Dis  \n                2003; \n                3\n                : 359-71.","journal-title":"Lancet Infect Dis"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1128\/AAC.44.11.3169-3173.2000","volume":"44","author":"Khan AA","year":"2000","unstructured":"Khan AA, Slifer TR, Araujo FG, Suzuki Y, Remington JS. \n                Protection against lipopolysaccharide-induced death by fluoroquinolones \n                Antimicrob Agents Chemother  \n                2000; \n                44\n                : 3169-73.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/dkf091","volume":"50","author":"Purswani MU","year":"2002","unstructured":"Purswani MU, Eckert SJ, Arora HK, Noel GJ. \n                Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model \n                J Antimicrob Chemother  \n                2002; \n                50\n                : 51-8.","journal-title":"J Antimicrob Chemother"},{"key":"refR45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1034\/j.1600-0609.2001.066005287.x","volume":"66","author":"Shalit I","year":"2001","unstructured":"Shalit I, Kletter Y, Halperin D, et al. \n                Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia \n                Eur J Haematol  \n                2001; \n                66\n                : 287-96.","journal-title":"Eur J Haematol"},{"key":"refR46","first-page":"35","volume":"8","author":"Zehavi-Willner T","year":"1989","unstructured":"Zehavi-Willner T, Shalit I. \n                Enhancement of interleukin-2 production in human lymphocytes by two new quinolone derivatives \n                Lymphokine Res  \n                1989; \n                8\n                : 35-46.","journal-title":"Lymphokine Res"},{"key":"refR47","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1128\/AAC.47.9.2749-2755.2003","volume":"47","author":"Scaglione F","year":"2003","unstructured":"Scaglione F, Mouton JW, Mattina R, Fraschini F. \n                Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration\/MIC versus area under the curve\/MIC ratios \n                Antimicrob Agents Chemother  \n                2003; \n                47\n                : 2749-55.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR48","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1016\/S0021-9258(18)62213-6","volume":"246","author":"Leighton TJ","year":"1971","unstructured":"Leighton TJ, Doi RH. \n                The stability of messenger ribonucleic acid during sporulation in Bacillus subtilis \n                J Biol Chem  \n                1971; \n                246\n                : 3189-95.","journal-title":"J Biol Chem"},{"key":"refR49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1472-765x.2002.01047.x","volume":"34","author":"Hamouda T","year":"2002","unstructured":"Hamouda T, Shih AY, Baker JR. \n                A rapid staining technique for the detection of the initiation of germination of bacterial spores \n                Lett Appl Microbiol  \n                2002; \n                34\n                : 86-90.","journal-title":"Lett Appl Microbiol"},{"key":"refR50","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1099\/mic.0.2008\/017335-0","volume":"154","author":"Agar SL","year":"2008","unstructured":"Agar SL, Sha J, Foltz SM, et al. \n                Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92 \n                Microbiology  \n                2008; \n                154\n                : 1939-48.","journal-title":"Microbiology"},{"key":"refR51","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/IAI.01529-07","volume":"76","author":"Sha J","year":"2008","unstructured":"Sha J, Agar SL, Baze WB, et al. \n                Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague \n                Infect Immun  \n                2008; \n                76\n                : 1390-409.","journal-title":"Infect Immun"},{"key":"refR52","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1128\/IAI.00157-07","volume":"75","author":"Gentry M","year":"2007","unstructured":"Gentry M, Taormina J, Pyles RB, et al. \n                Role of primary human alveolar epithelial cells in host defense against Francisella tularensis infection \n                Infect Immun  \n                2007; \n                75\n                : 3969-78.","journal-title":"Infect Immun"},{"key":"refR53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1570-0232(02)00046-6","volume":"772","author":"Liang H","year":"2002","unstructured":"Liang H, Kays MB, Sowinski KM. \n                Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma \n                J Chromatogr B Analyt Technol Biomed Life Sci  \n                2002; \n                772\n                : 53-63.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"refR54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00003226-200404000-00007","volume":"23","author":"Healy DP","year":"2003","unstructured":"Healy DP, Holland EJ, Nordlund ML, et al. \n                Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration \n                Cornea  \n                2003; \n                23\n                : 255-63.","journal-title":"Cornea"},{"key":"refR55","doi-asserted-by":"crossref","unstructured":"Gibaldi M, Perrier D. \n                Pharmacokinetics.  2nd. \n                New York, NY: Marcell Dekker, Inc 1982.","DOI":"10.1201\/b14095"},{"key":"refR56","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1128\/IAI.00352-07","volume":"75","author":"Peterson JW","year":"2007","unstructured":"Peterson JW, Comer JE, Baze WB, et al. \n                Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model \n                Infect Immun  \n                2007; \n                75\n                : 3414-24.","journal-title":"Infect Immun"},{"key":"refR57","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00802-09","volume":"53","author":"Drusano GL","year":"2009","unstructured":"Drusano GL, Okusanya OO, Okusanya AO, et al. \n                Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis \n                Antimicrob Agents Chemother  \n                2009; \n                53\n                : 4718-25.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/AAC.43.3.667","volume":"43","author":"Fernandez J","year":"1999","unstructured":"Fernandez J, Barrett JF, Licata L, Amaratunga D, Frosco M. \n                Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess \n                Antimicrob Agents Chemother  \n                1999; \n                43\n                : 667-71.","journal-title":"Antimicrob Agents Chemother"},{"key":"refR59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0924-8579(98)00087-9","volume":"12","author":"Onyeji CO","year":"1999","unstructured":"Onyeji CO, Bui KQ, Owens RC Jr, Nicolau DP, Quintiliani R, Nightingale CH. \n                Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia \n                Int J Antimicrob Agents  \n                1999; \n                12\n                : 107-4.","journal-title":"Int J Antimicrob Agents"},{"key":"refR60","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1073\/pnas.0602748103","volume":"103","author":"Vietri NJ","year":"2006","unstructured":"Vietri NJ, Purcell BK, Lawler JV, et al. \n                Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax \n                Proc Natl Acad Sci USA  \n                2006; \n                103\n                : 7813-6.","journal-title":"Proc Natl Acad Sci USA"},{"key":"refR61","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/JCM.01741-07","volume":"46","author":"Eguchi H","year":"2008","unstructured":"Eguchi H, Kuwahara T, Miyamoto T, et al. \n                High-level fluoroquinolone resistance in ophthalmic clinical isolates belonging to the species Corynebacterium macginleyi \n                J Clin Microbiol  \n                2008; \n                46\n                : 527-32.","journal-title":"J Clin Microbiol"},{"key":"refR62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s15010-007-6113-0","volume":"35","author":"Razavi B","year":"2007","unstructured":"Razavi B, Apisarnthanarak A, Mundy LM. \n                Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance \n                Infection  \n                2007; \n                35\n                : 300-7.","journal-title":"Infection"},{"key":"refR63","first-page":"423","volume":"30","author":"Zemkova M","year":"2007","unstructured":"Zemkova M, Kotlarova J, Merka V, Cermak P, Vlcek J, Jebavy L. \n                Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology \n                New Microbiol  \n                2007; \n                30\n                : 423-30.","journal-title":"New Microbiol"},{"key":"refR64","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199709043371004","volume":"337","author":"Galimand M","year":"1997","unstructured":"Galimand M, Guiyoule A, Gerbaud G, et al. \n                Multidrug resistance in Yersinia pestis mediated by a transferable plasmid \n                N Engl J Med  \n                1997; \n                337\n                : 677-80.","journal-title":"N Engl J Med"},{"key":"refR65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3201\/eid0701.010106","volume":"7","author":"Guiyoule A","year":"2001","unstructured":"Guiyoule A, Gerbaud G, Buchrieser C, et al. \n                Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis \n                Emerg Infect Dis  \n                2001; \n                7\n                : 43-8.","journal-title":"Emerg Infect Dis"},{"key":"refR66","unstructured":"Alibek K. \n                Combating Terrorism: Assessing the threat of a biological weapons attack \n                Testimony before a special congressional committee hearing In: Congressional committee Oct 22, 2001 edn: Newsmaxcom; 2001"},{"key":"refR67","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jac\/dkh258","volume":"54","author":"Athamna A","year":"2004","unstructured":"Athamna A, Athamna M, Abu-Rashed N, Medlej B, Bast DJ, Rubinstein E. \n                Selection of Bacillus anthracis isolates resistant to antibiotics \n                J Antimicrob Chemother  \n                2004; \n                54\n                : 424-8.","journal-title":"J Antimicrob Chemother"}],"container-title":["The Open Microbiology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openmicrobiologyjournal.com\/contents\/volumes\/V4\/TOMICROJ-4-34\/TOMICROJ-4-34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openmicrobiologyjournal.com\/contents\/volumes\/V4\/TOMICROJ-4-34\/TOMICROJ-4-34.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openmicrobiologyjournal.com\/contents\/volumes\/V4\/TOMICROJ-4-34\/TOMICROJ-4-34.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:26:35Z","timestamp":1761546395000},"score":1,"resource":{"primary":{"URL":"https:\/\/openmicrobiologyjournal.com\/VOLUME\/4\/PAGE\/34\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,3]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,6,3]]}},"alternative-id":["TOMICROJ-4-34"],"URL":"https:\/\/doi.org\/10.2174\/1874285801004010034","relation":{},"ISSN":["1874-2858"],"issn-type":[{"value":"1874-2858","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2010-4-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-4-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-4-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}